HC Wainwright Has Positive Forecast for AUTL Q1 Earnings

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) – Analysts at HC Wainwright increased their Q1 2026 EPS estimates for Autolus Therapeutics in a research report issued to clients and investors on Thursday, April 9th. HC Wainwright analyst E. Bodnar now forecasts that the company will post earnings per share of ($0.30) for the quarter, up from their prior estimate of ($0.33). HC Wainwright has a “Buy” rating and a $9.00 price objective on the stock. The consensus estimate for Autolus Therapeutics’ current full-year earnings is ($0.94) per share. HC Wainwright also issued estimates for Autolus Therapeutics’ Q2 2026 earnings at ($0.31) EPS, Q3 2026 earnings at ($0.30) EPS, Q4 2026 earnings at ($0.29) EPS, FY2026 earnings at ($1.21) EPS, FY2027 earnings at ($0.77) EPS, FY2028 earnings at ($0.57) EPS, FY2029 earnings at ($0.36) EPS and FY2030 earnings at ($0.19) EPS.

Autolus Therapeutics (NASDAQ:AUTL) last posted its earnings results on Friday, March 27th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.07). The firm had revenue of $24.29 million during the quarter, compared to analyst estimates of $23.92 million. Autolus Therapeutics had a negative return on equity of 99.05% and a negative net margin of 381.40%.

Several other equities research analysts have also weighed in on the stock. Zacks Research upgraded shares of Autolus Therapeutics from a “strong sell” rating to a “hold” rating in a report on Friday, March 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Autolus Therapeutics in a report on Wednesday, January 21st. Needham & Company LLC reiterated a “buy” rating and issued a $10.00 target price on shares of Autolus Therapeutics in a report on Thursday, April 9th. Mizuho cut their target price on shares of Autolus Therapeutics from $12.00 to $10.00 and set an “outperform” rating on the stock in a report on Tuesday, March 31st. Finally, Truist Financial upgraded shares of Autolus Therapeutics to a “strong-buy” rating in a report on Wednesday, March 25th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Autolus Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $8.50.

Autolus Therapeutics Stock Performance

AUTL opened at $1.47 on Monday. The firm’s fifty day moving average is $1.48 and its two-hundred day moving average is $1.52. The firm has a market cap of $391.23 million, a PE ratio of -1.36 and a beta of 2.04. Autolus Therapeutics has a twelve month low of $1.15 and a twelve month high of $2.70.

Institutional Investors Weigh In On Autolus Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Marex Group plc acquired a new stake in shares of Autolus Therapeutics during the second quarter worth $28,000. Independent Advisor Alliance acquired a new stake in shares of Autolus Therapeutics during the fourth quarter worth $28,000. SmartHarvest Portfolios LLC acquired a new stake in shares of Autolus Therapeutics during the fourth quarter worth $43,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Autolus Therapeutics during the third quarter worth $46,000. Finally, R Squared Ltd raised its holdings in shares of Autolus Therapeutics by 40.1% during the third quarter. R Squared Ltd now owns 30,476 shares of the company’s stock worth $50,000 after acquiring an additional 8,730 shares during the period. 72.83% of the stock is currently owned by institutional investors and hedge funds.

About Autolus Therapeutics

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.